
|Videos|April 25, 2022
Tucatinib for Metastatic HER2+ Breast Cancer and Brain Metastases: Patient Selection
Ruta Rao, MD, discusses her rationale for treating metastatic HER2+ breast cancer with a tucatinib-containing regimen based on data from the HER2CLIMB trial.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
2
The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?
3
Why Earlier CAR T-Cell Therapy May Benefit Patients With Multiple Myeloma
4
GLP-1 Receptor Agonists and Cancer: Renewed Momentum for Metabo-Oncology
5



























































